Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with hematologic malignancies including myelodysplastic syndrome (MDS), who are at a high risk of complications after myeloablative transplantation~* Patients have a donor (both related and unrelated) who are mismatched according to protocol criteria~* 18 years of age or older~* Performance status 0-2~* Life expectancy of \> 100 days~* Female subject is either post-menopausal or sterilized or willing to use an acceptable form of birth control~* Male subject agrees to use an acceptable form of birth control~Exclusion Criteria:~* Evidence of HIV infection~* Total bilirubin \> 2.0mg/dl that is due to hepatocellular dysfunction~* Aspartate aminotransferase (AST) \> 90~* Known active hepatitis B or C~* Serum creatinine \> 2.0~* Greater than or equal to Grade 2 peripheral neuropathy within 21 days of enrollment~* Prior allogeneic stem cell transplant~* Patients with myeloproliferative disease (e.g. myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia)~* Myocardial infarction within 6 months prior to enrollment or has NYHA Class III or IV hear failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities~* Hypersensitivity to Velcade, boron or mannitol~* Pregnant or breast feeding~* Patient has received other investigational drugs 14 days before enrollment~* Serious medical or psychiatric illness~* Another active solid tumor malignancy at the time of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bortezomib/Tacrolimus/Methotrexate post HSCT (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).